Highlights
- Clobetasol propionate ophthalmic suspension (CPN) 0.05% (BYQLOVI®) is the first super-potent (Class I) corticosteroid formulated for ophthalmic use.
- Pooled Phase 3 data (CPN-301 and CPN-302) demonstrate that twice-daily (BID) dosing for 14 days achieves significantly higher rates of anterior chamber cell (ACC) clearance (58.2% vs. 17.3%) and pain resolution (88.5% vs. 45.8%) compared to placebo.
- Unlike traditional high-potency steroids, CPN 0.05% shows no clinically meaningful increases in intraocular pressure (IOP) or deleterious effects on corneal endothelial cell density.
- The rapid onset of action is evidenced by significant visual acuity improvements and pain relief as early as post-operative day (POD) 4.
Background
Cataract surgery, while routine and highly successful, triggers an immediate inflammatory cascade within the anterior segment. The surgical trauma induces the release of prostaglandins and various cytokines, leading to anterior chamber flare, cellular infiltration, and ocular pain. If inadequately managed, post-operative inflammation can result in secondary complications such as cystoid macular edema (CME), posterior synechiae, or delayed visual recovery.
Traditionally, topical corticosteroids (e.g., prednisolone acetate 1% or dexamethasone) have been the cornerstone of management. However, these often require frequent dosing (QID or more) and carry risks of steroid-induced ocular hypertension. Clobetasol propionate, a well-established super-potent dermatological steroid, has recently been adapted into an ophthalmic suspension (BYQLOVI®) to address the need for a high-potency, low-frequency dosing regimen with a safer ocular profile.
Key Content
The Clinical Evolution of Clobetasol Propionate Ophthalmic Suspension
The development of CPN 0.05% followed a rigorous dose-selection pathway. Early studies (PMID: 41329923) utilized a two-part design (Part A and Part B) to evaluate various concentrations and frequencies. Results indicated that 0.05% BID for 14 to 21 days was the optimal regimen, significantly reducing ACC counts and flare compared to placebo. Interestingly, regimens involving a taper to once-daily dosing were found to be less efficacious than the sustained BID 14-day protocol, establishing the 0.05% BID regimen as the standard for further Phase 3 investigation.
Phase 3 Synthesis: Efficacy and Rapid Recovery
The pivotal evidence for CPN 0.05% stems from the pooled analysis of two multicenter, randomized, double-masked Phase 3 trials (CPN-301 and CPN-302, PMID: 42097332). In these studies, 748 participants undergoing uncomplicated cataract surgery were randomized to receive either CPN 0.05% or a placebo vehicle BID for 14 days.
Efficacy outcomes were robust:
- Inflammation Clearance: At POD 15, 58.2% of the CPN group achieved an ACC count of 0, compared to only 17.3% in the placebo group (p < 0.001).
- Pain Resolution: By POD 4, a staggering 88.5% of CPN-treated patients were entirely pain-free, a state maintained through POD 15, significantly outperforming the placebo at 45.8% (p < 0.001).
- Visual Rehabilitation: Visual acuity improved more rapidly in the CPN 0.05% group by POD 4, suggesting that faster control of inflammation directly translates to quicker functional recovery for the patient.
Notably, there was no evidence of a “rebound effect”—a common concern with potent steroids—when the medication was discontinued after 14 days, as inflammatory markers remained stable at the POD 22 follow-up.
Safety and Corneal Integrity
A critical differentiator for CPN 0.05% is its safety profile. In CPN-302, a dedicated sub-study focused on corneal endothelial cell (EC) safety. High-potency steroids can sometimes interfere with corneal metabolism; however, CPN 0.05% showed no significant changes in EC density compared to placebo. Furthermore, the risk of steroid-induced IOP spikes—a major limitation of prednisolone—was not observed with CPN 0.05%. The incidence of adverse events was comparable to the vehicle group, and significantly fewer patients in the CPN group required rescue medications, further underscoring its therapeutic reliability.
Comparative Context: Steroids and NSAIDs
The landscape of post-operative care includes various classes of anti-inflammatories. Evidence for OCS-01 (a novel dexamethasone 1.5% formulation, PMID: 36503736) also shows efficacy with once-daily or BID dosing, reflecting a broader trend toward reducing the drop burden.
Historically, rimexolone 1% (PMID: 17762913, 15085979) was marketed as a safer alternative to prednisolone acetate regarding IOP, though it offered similar efficacy. Non-steroidal anti-inflammatory drugs (NSAIDs) like nepafenac (PMID: 24345529, 19040348) and bromfenac (PMID: 33727659) have also demonstrated success, particularly when used as adjuncts to steroids to prevent macular swelling (PMID: 25135542). However, CPN 0.05% stands out as a monotherapy option that combines the highest tier of steroid potency with a dosing frequency (BID) that matches or beats modern NSAID/steroid combinations.
Expert Commentary
The Rationale for Super-Potency
Clobetasol propionate is a Class I corticosteroid, traditionally reserved for severe dermatological conditions due to its high affinity for the glucocorticoid receptor. Translating this to ophthalmology requires a suspension that can penetrate the ocular surface effectively without inducing systemic side effects or localized tissue toxicity. The clinical success of BYQLOVI® suggests that by utilizing a super-potent molecule, we can achieve therapeutic thresholds in the aqueous humor with fewer applications (BID vs. QID), which significantly improves patient compliance—a major factor in surgical success among the elderly cataract population.
Addressing the IOP Concern
One of the most impressive findings in the CPN Phase 3 trials is the lack of IOP elevation. This may be due to the specific molecular structure of clobetasol propionate or its metabolic pathway within the anterior chamber. Clinicians have long sought a “potent but safe” steroid to replace prednisolone acetate, which, while effective, is a known “strong” steroid for inducing ocular hypertension in susceptible individuals.
Clinical Applicability and Future Directions
CPN 0.05% is particularly suited for patients at high risk for significant post-operative inflammation (e.g., those with long surgical times or complex maneuvers) or those likely to struggle with complex dosing schedules. While the current studies focus on uncomplicated cataract surgery, future research should explore its efficacy in complex cases, such as combined cataract-glaucoma procedures or in patients with pre-existing uveitis.
Conclusion
The approval and clinical validation of Clobetasol Propionate Ophthalmic Suspension 0.05% (BYQLOVI®) represent a significant advancement in ophthalmic pharmacology. By providing rapid clearance of inflammation and nearly total pain resolution with a convenient twice-daily regimen, it addresses both clinical efficacy and patient compliance. Its proven safety profile regarding intraocular pressure and the corneal endothelium positions it as a potential first-line standard for post-operative care following cataract surgery.
References
- Korenfeld MS, Levenson J, Sadri E, et al. Clobetasol Propionate Ophthalmic Suspension (BYQLOVI®) to Treat Ocular Inflammation and Pain after Uncomplicated Cataract Surgery. Ophthalmology. 2026; (In Press). PMID: 42097332.
- Dose-selection study of clobetasol propionate ophthalmic suspension that evaluated inflammation and pain after cataract surgery. J Cataract Refract Surg. 2026;52(5):444-451. PMID: 41329923.
- Modi S, et al. Once-daily nepafenac ophthalmic suspension 0.3% to prevent and treat ocular inflammation and pain after cataract surgery: phase 3 study. J Cataract Refract Surg. 2014;40(2):203-11. PMID: 24345529.
- Sane ME, et al. OCS-01 (Novel Topical Dexamethasone Formulation) in Inflammation and Pain Post Cataract Surgery: A Randomized, Double-Masked, Vehicle-Controlled Study. Clin Ther. 2022;44(12):1577-1587. PMID: 36503736.
- Kavroulaki D, et al. Rimexolone 1% versus prednisolone acetate in preventing early postoperative inflammation after cataract surgery. Int Ophthalmol. 2008;28(4):281-5. PMID: 17762913.
